Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells $53,950.00 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 500 shares of the stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $107.90, for a total transaction of $53,950.00. Following the sale, the chief executive officer now owns 438,473 shares of the company’s stock, valued at $47,311,236.70. This trade represents a 0.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $111.13 on Friday. The company has a market cap of $6.85 billion, a price-to-earnings ratio of 15.65, a PEG ratio of 1.04 and a beta of 0.33. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06. The company’s fifty day simple moving average is $108.09 and its 200 day simple moving average is $121.00. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The company had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. During the same quarter in the prior year, the firm earned $2.68 earnings per share. Jazz Pharmaceuticals’s revenue for the quarter was down .5% on a year-over-year basis. On average, research analysts forecast that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on JAZZ shares. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the company from $145.00 to $179.00 in a research report on Friday, March 7th. Royal Bank of Canada reduced their price objective on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. JPMorgan Chase & Co. lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Morgan Stanley cut their price target on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 7th. Finally, Barclays reaffirmed an “overweight” rating and issued a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $184.00.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. LSV Asset Management boosted its position in shares of Jazz Pharmaceuticals by 1.5% in the fourth quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company’s stock valued at $311,699,000 after acquiring an additional 37,108 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Jazz Pharmaceuticals by 14.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock valued at $289,066,000 after buying an additional 293,360 shares during the period. Capital World Investors increased its stake in shares of Jazz Pharmaceuticals by 5.7% in the fourth quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company’s stock valued at $236,860,000 after buying an additional 104,195 shares during the period. Ameriprise Financial Inc. increased its position in Jazz Pharmaceuticals by 20.9% during the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after purchasing an additional 315,608 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of Jazz Pharmaceuticals by 4.7% during the 1st quarter. JPMorgan Chase & Co. now owns 1,662,042 shares of the specialty pharmaceutical company’s stock worth $206,343,000 after buying an additional 74,501 shares during the period. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.